StockUS listing USCANFAMEXHealthcareValue Trap

Can Fite Biopharma Ltd ADR(CANF) Stock Analysis | Healthcare

USD --+0.00%
Reward44Moderate
Risk29Low
75%Data
USD —+0.00 (+0.00%) Previous close · AMEX
Market cap 4.35M
Reward Ratingⓘ44 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ29 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CANF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Can Fite Biopharma Ltd ADR?

, a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.

AI Brief Pro

The brief on Can Fite Biopharma Ltd ADR

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Can Fite Biopharma Ltd ADR?

, a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. The company is listed on the AMEX in USA, operating in the Healthcare sector, with a market capitalisation of 4.35M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (44)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.003
Insider Activity
12M windowNo data
No insider activity data available for this ticker.